Novartis says EU approves expanded use of Glivec

Swiss pharmaceutical group Novartis said Monday the European Union will allow it to expand its use of the drug Glivec to treat certain rare forms of gastrointestinal cancer.

The European Commission approved an update to the Glivec label to include 36 months of treatment after surgery "for adults with KIT (CD117)-positive (GIST)," Novartis said in a statement.

"Gastrointestinal stromal tumors are a rare, life-threatening cancer of the ," it said.

They are often difficult to diagnose and treat because they may not cause physical symptoms.

The cancers are usually diagnosed in patients aged between 55 and 65, and are characterised by tumors of connective tissue supporting the digestive tract.

Last year Novartis said sales of Glivec reached $4.7 billion (3.5 billion euros).

Related Stories

'Rare' cancers in the spotlight at major European conference

date Feb 24, 2010

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and ...

Drug shows promise as new treatment for gut tumor

date Jan 11, 2010

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh ...

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.